Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Capital Leases (2020 - 2025)

Historic Capital Leases for Ptc Therapeutics (PTCT) over the last 6 years, with Q3 2025 value amounting to $13.8 million.

  • Ptc Therapeutics' Capital Leases fell 1117.89% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year decrease of 1117.89%. This contributed to the annual value of $15.6 million for FY2024, which is 936.92% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Capital Leases of $13.8 million as of Q3 2025, which was down 1117.89% from $13.8 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Capital Leases ranged from a high of $20.1 million in Q3 2021 and a low of $13.8 million during Q1 2025
  • For the 5-year period, Ptc Therapeutics' Capital Leases averaged around $17.2 million, with its median value being $17.2 million (2023).
  • As far as peak fluctuations go, Ptc Therapeutics' Capital Leases crashed by 1298.7% in 2021, and later crashed by 674.71% in 2022.
  • Ptc Therapeutics' Capital Leases (Quarter) stood at $20.1 million in 2021, then fell by 7.09% to $18.7 million in 2022, then fell by 7.98% to $17.2 million in 2023, then fell by 9.37% to $15.6 million in 2024, then fell by 11.18% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $13.8 million for Q2 2025, and $13.8 million during Q1 2025.